BORA EXPANDIR
Aguardando prazo de apresentação de oposição
Marca Nominativa depositada no INPI em
19/06/2025 por BORA EXPANDIR LTDA,
processo nº 939651793, nas classes 05, 40, 42, 44.
O processo ainda está em andamento no INPI.
| Número do processo | 939651793 |
|---|
| Situação | Aguardando prazo de apresentação de oposição |
|---|
| Apresentação | Nominativa |
|---|
| Natureza | Produtos e/ou Serviço |
|---|
| Data do depósito | 19/06/2025 |
|---|
| Data da concessão | — |
|---|
| Vigência até | — |
|---|
| Titular | BORA EXPANDIR LTDA |
|---|
| CNPJ do titular | 55.218.947/0001-65 |
|---|
| UF · País | SP · BR |
|---|
Classes e especificação
Medical and veterinary preparations for therapeutic purposes; preparations for cell therapy; preparations for gene therapy; preparations for cancer therapies; preparations for autoimmune diseases; chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; pharmaceutical preparations; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; vaccines.;
Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines.;
Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services.;
Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines.;